27262-39-1

Basic information

• Product Name: (S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate
• CAS NO: 27262-39-1
• Molecular Weight: 822.956
• Mol File: 27262-39-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate(27262-39-1)
• EPA Substance Registry System: (S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate(27262-39-1)

Safety Data

• Hazardous Substances Data: 27262-39-1(Hazardous Substances Data)

Usage

General Description

(S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate is a chemical compound that is commonly used as a local anesthetic. It is a salt of the L-tartrate ester of (S)-bupivacaine, a long-acting amide-type local anesthetic. (S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate works by blocking the transmission of pain signals from nerves to the brain, resulting in numbness and loss of sensation in a specific area of the body. It is often used in medical and dental procedures as well as for pain management after surgery. Additionally, (S)-dibenzoyl-2-pipecolinoxylidide-L-tartrate is also being studied for its potential in treating chronic pain conditions and as a component of epidural anesthesia. However, like any medication, it can have side effects and should be used under the supervision of a healthcare professional.

Upstream product

• 4043-87-2 pipecolic Acid 
• 15883-20-2 2',6'-pipecoloxylidide 
• 2743-38-6 O,O'-dibenzoyl-L-tartaric acid 
• 65797-42-4 (+/-)-2',6'-pipecoloxylidide hydrochloride 

Downstream Products

• 27262-40-4 (S)-2',6'-pipecoloxylidide 

Relevant articles and documents

Synthesis, biological evaluation, and molecular docking of ropivacaine analogs as local anesthetic agents

Two series of ropivacaine analogs (4a–4q, 7a–7c) were synthesized, and their biological activities were evaluated as local anesthetic agents. Most of the compounds displayed detectable local anesthetic characteristics. Among them, compound 4l showed significant efficacy with sciatic nerve block, infiltration, corneal surface, and spinal anesthetic activities. It was as potent as the reference compound ropivacaine. Dissociation constants of these compounds were 5.9–7.9. In addition, molecular docking modeling on compound 4l and ropivacaine was performed to delineate structural requirements and potential mechanisms for the local anesthetic activity. This study provides valuable new information for our ongoing endeavor to design more potent local anesthetics.

ROPIVACAINE HYDROCHLORIDE ANHYDRATE AND THE PREPARATION THEREOF

The invention pertains to a process for preparing stable anhydrous Ropivacaine hydrochloride, the process involving preparing Ropivacaine hydrochloride from Ropivacaine base, wherein Ropivacaine base is provided having a chiral purity of more than 95 %, a